FIRST ONCOLYTIC VIRAL THERAPY APPROVED FOR HEAD AND NECK CANCER

Shanghai Sunway Biotech Co. Ltd. announced today that the Chinese State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory Nasopharyngeal cancer, a type of head and neck cancer prevalent in China. This marks the first oncolytic viral therapy approved by any regulatory agency in the world.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1108957XSL_NEWSML_TO_NEWSML_WEB.xml)